Professor Stephen Davis
Professor Davis is the Director of the MBC-RM. He is the inaugural Professor of Translational Neuroscience at the University of Melbourne. At RMH, he is Director of Neurosciences and Continuing Care at RMH and Director of Neurology.
He is the immediate past-President of the Australian and New Zealand Association of Neurologists (ANZAN) and a past-President of the Stroke Society of Australasia. He was the first Co-chair of the Australasian Stroke Trials network and Co-Chair of the World Stroke Academy.
In 2012, he was appointed President of the World Stroke Organization. He is the Co-Chair, with Professor Geoffrey Donnan, of Neuroscience Trials Australia (NTA) and has been a trustee of The Royal Melbourne Hospital Neuroscience Foundation since its formation in 1992.
He is a Consulting Editor for Stroke and Associate Editor for Cerebrovascular Diseases. His major research interests involve clinical trials in stroke and the use of neuroimaging, particularly multimodal MRI, in the selection of acute stroke treatments.
Professor Helmut Butzkueven
Professor Butzkueven is joint Director of the MS Service at The Royal Melbourne Hospital and Director of the MS service at Box Hill Hospital, Melbourne, Australia. He is a Professor in the Department of Medicine, University of Melbourne and a Deputy Director of the MBC-RMH. He is the Chairman of the MSBase Foundation (www.msbase.org) that funds and administers a global online MS cohort study with more than 20 300 patients enrolled in 64 centres across 27 countries.
His research interests focus on two areas of Multiple Sclerosis Research; development of new biomarkers for axonal degeneration in MS and understanding the effects of MS risk genes.
Associate Professor Kate Drummond
Associate Professor Drummond is a Neurosurgeon at The Royal Melbourne Hospital, Associate Professor at The University of Melbourne and a Deputy Director of the MBC-RMH. She has published more than 40 peer reviewed articles, many book chapters and is frequently invited to speak nationally and internationally. She has led the multidisciplinary brain tumour service with Professor Mark Rosenthal in a number of international brain tumour research programs, including initiating a number of important clinical trials at The Royal Melbourne Hospital.
The brain tumour service specializes in “first-in human” Phase I trials of novel agents, and also functions as a brain tumour bank, collecting tissue and data on all consenting brain tumour patients. Associate Professor Drummond’s chief research and clinical interests are in the biology and management of brain tumours.
Professor Terence O'Brien
Professor O’Brien is the James Stewart Professor of Medicine, Head of The Department of Medicine (Royal Melbourne Hospital) at The University of Melbourne and Consultant Neurologist at The Royal Melbourne Hospital, Victoria, Australia. He leads a large translational research team undertaking both basic studies, involving animal models, and clinical studies.
He is a specialist in neurology and clinical pharmacology, with particular expertise in epileptology, anti-epileptic drugs and in-vivo imaging in animal models and humans. His key research goals are to identify novel treatment approaches for epilepsy and the associated neuropsychiatric co-morbidities, and to identify biomarkers – clinical, imaging, electrophysiological and genomic – of treatment in individual patients.